Current Report Filing (8-k)
April 11 2018 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report:
April 10, 2018
Commission File
Number
000-53230
PEPTIDE TECHNOLOGIES, INC.
(Exact name of
registrant as specified in its charter)
Nevada
|
|
98-0479983
|
State
or other jurisdiction of
|
|
(I.R.S.
Employer
|
incorporation
or organization
|
|
Identification
No.)
|
5348 Vegas Drive #177 Las Vegas, NV 89108
(Address of
principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (702)
948-8893
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company [ ]
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
|
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Resignation of Officers
As included in the Corporate Form 10-Q filed February 8, 2018,
this will confirm that effective November 7, 2017, Dennis Cox, who served as
President and a Director of Peptide Technologies, Inc., has resigned as
President. Mr. Cox will remain as a Director.
Appointment
of Board Members and Officer
As also included in the
Corporate Form 10-Q filed February 8, 2018, this will confirm that on November 7, 2017, Byron Striloff was appointed to
serve as President of Peptide Technologies, Inc.. Mr. Byron Striloff spent 35
years as a senior investment advisor in the areas of personal and corporate
investment management, tax planning, venture capital, insurance, and estate
planning. He was a producing branch manager and has held senior management and
directorship positions for various national investment dealers. His most recent
account executive position as a senior personal and corporate investment
advisor from 2012 through January 2016 was with CIBC Wood Gundy. He is also
presently a Director of Nationwide Self Storage and a Trustee for Valhalla
Diamond Trust.
His primary area of specialization is the
development of financial strategies that optimize investment performance from
long-term trends, tax minimization, and wealth creation for individuals and
businesses. He is also a master qualified member of the Dent Foundation and
frequently speaks at public seminars on demographic economic forecasting.
In consideration for accepting the appointment as a President
for the Company, five million (5,000,000) fully
vested shares of the Company's restricted common stock shall be
issued to Byron Striloff.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned, hereunto
duly authorized.
PEPTIDE
TECHNOLOGIES, INC.
By:
/s/ Baxter
Koehn
Chairman
of the Board
Date:
April 10, 2018